SCHEDULE 13G: Tang Capital Discloses 6.6% Stake in Capricor Therapeutics

Tang Capital Management and affiliated entities have reported a 6.6% beneficial ownership stake in Capricor Therapeutics, Inc. as of January 16, 2026.

Summary

• Tang Capital Management, LLC, Kevin Tang, Tang Capital Partners, LP, and Tang Capital Partners International, LP collectively beneficially own 3,399,900 shares of Capricor Therapeutics, Inc. common stock.
• This ownership represents 6.6% of the total outstanding common stock of Capricor Therapeutics, Inc.
• The percentage is calculated based on 51,716,975 shares outstanding as of December 8, 2025, as reported in a Form 424(b)(5) prospectus.
• The shares were not acquired for the purpose of changing or influencing control of the issuer, except for activities solely related to a nomination under Rule 14a-11.

Sentiment

Score: 6

Explanation: The filing is neutral in tone, simply reporting a beneficial ownership stake. The presence of a significant institutional investor can be seen as a mild positive signal, but it doesn't provide operational or financial performance data.

Positives

• A significant institutional investor, Tang Capital, has taken a notable stake in Capricor Therapeutics, potentially signaling confidence in the company's future.
• The filing indicates a passive investment strategy, suggesting no immediate intent to influence control, which can provide stability.

Risks

• The filing itself does not detail risks of the issuer, but rather the nature of the holding. The standard certification states the shares are not held for the purpose of changing or influencing control, which mitigates the risk of an activist campaign from this specific filing.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding Capricor Therapeutics' future operations or financial performance, focusing solely on beneficial ownership.

Management Comments

• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This filing indicates a significant investment by a specialized capital management firm in a biotechnology company. Such investments are common in the biotech sector, where firms often take positions in companies with promising drug pipelines or technologies, anticipating future growth.

Comparison to Industry Standards

• A 6.6% stake is a substantial passive investment, often seen from institutional investors in the biotechnology sector, similar to holdings by funds like ARK Invest in innovative biotech firms or BlackRock in established pharmaceutical companies.
• Tang Capital Management's focus on life sciences suggests this investment aligns with their typical strategy of identifying undervalued or high-potential companies in the healthcare space.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake might be viewed positively, potentially increasing investor confidence.
• Management: The passive nature of the investment (as stated in the certification) suggests no immediate pressure for strategic changes from this specific filing.

Next Steps

• Capricor Therapeutics will continue its operations as a publicly traded company.
• Tang Capital Management and its affiliates will continue to hold their beneficial ownership in Capricor Therapeutics.

Key Dates

Recommendation

This Schedule 13G filing primarily discloses a significant passive ownership stake by Tang Capital Management and its affiliates in Capricor Therapeutics. While the presence of a notable institutional investor can be a positive signal, the filing itself provides no new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and await further company-specific news or financial reports to assess the company's fundamental value and future prospects.

Keywords

Capricor Therapeutics, Tang Capital Management, Kevin Tang, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Investment, SEC Filing